Why pelacarsen failed to cut heart risk despite Lp(a) drop
Pelacarsen, Novartis’s once-promising Lp(a)-lowering drug, failed to cut heart attacks, strokes, cardiovascular deaths, or urgent artery procedures in a large Phase III trial—despite lowering lipoprotein(a) by about 78%. Novo Nordisk’s ziltivekimab also missed its heart-event goals, stunning cardiologists.
Results presented Nov. 7 at the American Heart Association meeting in Chicago, and published in The New England Journal of Medicine, showed the outcome was not a near miss. “It didn’t do anything. It was completely neutral,” said Dr. Steven Nissen of the Cleveland Clinic, who led the pelacarsen study. For more medical puzzles, see our True Crime & Unsolved Mysteries desk.
Key Takeaways
- Pelacarsen cut Lp(a) by roughly 77–78% but did not reduce major cardiovascular events versus placebo.
- Roughly 12% of patients in each arm of the Novartis trial had a serious heart-related event.
- Novo Nordisk’s ziltivekimab lowered inflammation yet failed to cut deaths, heart attacks, or strokes in about 6,300 high-risk patients.
- Novartis is abandoning pelacarsen; other Lp(a) drugs from Amgen and Eli Lilly remain in late-stage trials.
- Experts still urge exercise, weight loss, and aggressive LDL control for people with high Lp(a).
What happened in the pelacarsen heart trial?
Researchers randomly assigned more than 8,300 people with prior heart attacks or strokes and high Lp(a) to a monthly 70 mg dose of pelacarsen or placebo. They were followed for a median of about 4.7 years. Other risks, including LDL cholesterol and blood pressure, were carefully controlled.
Pelacarsen did what chemists expected: it interfered with the body’s production of Lp(a) and drove levels down by an average of about 77%, according to CNN’s report on the findings. But rates of major adverse cardiovascular events—cardiovascular death, nonfatal heart attack, stroke, or urgent revascularization—were essentially identical, about 12% in each group.
About 20.6% of patients stopped pelacarsen because of side effects, compared with 7.5% on placebo. Secondary looks, including people with the highest baseline Lp(a), still showed no benefit. Dr. Fatima Rodriguez of Stanford said she was “flabbergasted,” adding there was “no signal.”
Why did Novo Nordisk’s heart drug also fail?
On the same meeting day, Dr. Paul Ridker of Brigham and Women’s Hospital presented results for Novo Nordisk’s ziltivekimab, which blocks interleukin-6 to calm heart-related inflammation. In roughly 6,300 patients with heart disease, advanced kidney disease, and systemic inflammation, the drug lowered inflammatory markers but did not reduce death, heart attack, or stroke versus placebo.
Novo had already said in July that the study missed its goal. In September it also stopped two other late-stage ziltivekimab trials in heart failure after monitors judged them unlikely to succeed. Ridker and other experts suggested patients may have been too sick for anti-inflammatory therapy to reverse years of damage.
Does high Lp(a) still matter after pelacarsen?
High Lp(a) is an inherited risk thought to affect about one in five people worldwide. Guidelines this year urged at least one lifetime Lp(a) test for adults, even though no specific treatment exists. The failed trial raises hard questions: Was the drug too weak, the patients too far along, or the biology misunderstood?
Nissen noted rivals using siRNA, such as Amgen’s olpasiran and Eli Lilly’s lepodisiran, can cut Lp(a) by around 95% and enroll more people who have never had a first event. Until those readouts, he and others say patients with high Lp(a) should still exercise, lose weight if needed, and push LDL as low as possible with a statin. “I got thrown off the horse,” Nissen said. “I’m going to get back on the horse.”